FDA approves new drug for advanced head and neck squamous cell carcinoma
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.
Rybrevant Faspro received accelerated approval, the first approval in 10 years of a drug for recurrent or metastatic HNSCC in patients with prior receipt of platinum-based chemotherapy. It is not indicated for treatment of oropharyngeal squamous cell carcinoma associated with human papillomavirus.
The approval is based on a trial of 102 patients with recurrent or metastatic HNSCC. Rybrevant Faspro had an overall response rate of 42% compared with 20% for currently approved therapies. Among patients who had a response to Rybrevant Faspro, 56% had a response lasting six months or longer.
"Today's approval represents a meaningful step forward for patients with HNSCC, a disease where treatment options have historically been limited and outcomes remain poor," Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, said in a statement.
Citation : FDA approves new drug for advanced head and neck squamous cell carcinoma (2026, November 17) retrieved 17 November 2026 from https://medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission.
Source link







